What Carofertin Treats: Main Uses and Benefits

Carofertin is commonly used in situations involving certain distressing symptoms linked to nutritional status and is relevant for addressing symptoms related to systemic imbalance stemming from insufficient dietary supply of beta-carotene. The supplement is applied across domains where additional symptomatic support is needed in contexts related to reproduction.

Supporting Fertility and Peripartum Health

This supplement is relevant in contexts marked by increased discomfort or tension related to reproduction. It may assist with managing symptom clusters that interfere with daily comfort, such as poor conception rates or delays in returning to productive breeding status. It is also used to help manage risk factors in conditions associated with acute or disruptive episodes, such as those that may lead to retention of placenta. The therapeutic benefit may contribute to easing the overall symptom load associated with insufficient nutritional supply during high-production phases.

“The primary goal is commonly used to help with providing supportive relief during phases when symptoms that create noticeable physiological strain become more noticeable.”

Regulatory References

1. VMD UK Product Information Database

The official regulatory documents strictly define the population eligibility for Carofertin, restricting its use to specific target species and imposing clear prohibitions based on age and pre-existing conditions.

Eligibility Scope

Regulatory Summary

The eligibility profile is governed by absolute contraindications as defined in the official regulatory documents. The age-related prohibition for use in newborn animals is explicitly linked to the content of the excipient benzyl alcohol within the formulation. Furthermore, any animal with a documented hypersensitivity to the Beta-Carotene active substance or to an excipient, such as macrogol stearate, is considered ineligible. The use of the product is strictly limited to the designated adult target species: cows/heifers and sows.

Interactions with other medicines and products

This section summarizes the official interaction information for Carofertin (Beta-carotene) as stated in authoritative government regulatory documents, such as the Summary of Product Characteristics (SPC) from regulatory bodies.

Systemic Interaction Profile

The regulatory label for Carofertin explicitly states that no interactions with other medicinal products are known. This declaration signifies that government-approved prescribing information does not list any systemic drug-drug, drug-food, or drug-supplement interactions that require cautionary administration or dosage adjustment based on current clinical and non-clinical data.

Procedural Constraints

Although no systemic interactions are documented, the regulatory documents specify an essential procedural constraint related to co-administration. Carofertin must not be physically mixed with any other veterinary medicinal products in the same syringe or container. This restriction is mandated due to the absence of compatibility studies, ensuring the stability and safety of the final preparation prior to injection.

Carofertin's activity is rooted in the dual mechanistic actions of Beta-Carotene, modulating gene transcription and providing direct molecular neutralization. The provitamin mechanism is initiated by the enzymatic cleavage of Beta-Carotene into Vitamin A precursors by the beta-carotene 15,15'-dioxygenase ( BCMO1) enzyme. The active metabolite, Retinoic Acid, functions as a ligand that binds to nuclear receptors ( RARs/ RXRs), directly regulating the transcription of specific genes that governs cellular maintenance and differentiation processes. This pathway results in changes to gene expression that modulate processes supporting systemic homeostasis and the integrity of epithelial and reproductive systems. The direct antioxidant mechanism relies on Beta-Carotene's conjugated structure to chemically quench Reactive Oxygen Species ( ROS) and Singlet Oxygen (^1O2). This chemical neutralization prevents destructive lipid peroxidation in cell membranes, resulting in a reduction of ROS that can influence cellular stability. This action influences highly metabolically active tissues, such as those involved in reproductive processes.

The administration of Carofertin follows a structured, non-oral protocol. The product, an emulsion, is delivered only via intramuscular injection or subcutaneous injection. Dosing varies based on the target species: Cows and Heifers are administered 20–25 ml per dose, while Sows and Gilts receive 7 ml. Procedurally, the large bovine dose must be divided and administered across several separate injection sites.

The frequency of use is intermittent and cyclical. Non-pregnant animals may receive up to three total doses over the course of treatment, provided a mandatory minimum interval of 14 days is strictly observed between each administration. The treatment schedule is further differentiated by reproductive status: pregnant Sows and Gilts receive a single dose with time-sensitive delivery, specified as 1–2 weeks ante-partum (before the expected date of farrowing). This timing and dose-volume differentiation define the usage protocol, which also includes the requirement that the container is used in one run on multiple animals, with all remaining contents immediately discarded.

Carofertin: Recent Clinical Evidence

Evidence for Nutritional Support and Reproductive Health

The research base for Carofertin, a beta-carotene supplement, focuses on research exploring nutritional deficiency related to reproductive function in cattle. The evidence includes Randomized Controlled Trials (RCTs) and comprehensive scientific reviews. Key research questions examined beta-carotene supplementation and its association with reproductive status in the animals studied, often within the context of systemic imbalance.

Findings indicate patterns where the injection method was associated with a measured increase in beta-carotene concentration in the blood. However, the link between this biomarker increase and changes in final clinical reproductive outcomes, such as pregnancy rates, was observed in some studies, but results were inconsistent across the broader evidence landscape.

Study Focus and Outcomes Measured

Trials evaluating beta-carotene interventions focused on two primary outcomes. The first included clinical endpoints like first service conception rate, overall pregnancy rate, and the time interval for cows to return to breeding status after calving. The second category involved physiological biomarkers such as plasma beta-Carotene concentration and hormone levels like Progesterone ( P4). Data show patterns related to inconsistent findings when correlating the physiological biomarker shift with the clinical outcomes monitored.

Evidence in Special Populations and Limitations

Research focuses heavily on lactating dairy cows and animals in the postpartum period, often those with pre-existing low beta-carotene levels. Currently, data for certain groups remain insufficient; for example, there is limited information for how the evidence applies to populations outside of dairy cattle, such as beef cattle.

The follow-up durations used in the research were limited, typically spanning up to 150 days postpartum. Consequently, long-term effects are not fully established. The main area of uncertainty relates to the translation of a measured change in the biomarker into consistent shifts in clinical outcomes. Evidence quality varies across studies, and some trials used sample sizes that were modest.

Key Studies & References

1. SPC - Carofertin, 50 mg/ml Emulsion for Injection (Official Veterinary Product Information)

Common questions about Carofertin (FAQ)

Q: Are there any long-term safety concerns or risks associated with taking Carofertin for many years?

A: Long-term effects are not fully established in the available research data. This is because clinical research follow-up in the target species was typically limited to periods, such as 150 days postpartum.

Q: What is the significance of the inactive ingredients listed in Carofertin?

A: The excipient benzyl alcohol is specifically noted in the official regulatory documents. The presence of this inactive ingredient is the reason the product is contraindicated (not allowed) for use in newborn animals.

Q: Is there a way to verify if Carofertin contains a substance that is banned by sports organizations?

A: The active ingredient is Beta-Carotene, a Provitamin A Carotenoid. For specific competitions or events, it is advisable to check the full ingredient list against the rules and regulations provided by the relevant anti-doping authority.

Q: How is Carofertin classified in terms of risk during pregnancy, like an FDA pregnancy category?

A: According to the official product information, the use of this medicine is permitted during both the pregnancy and lactation phases in the target species (cattle and pigs). Formal human risk classification systems, such as the historical FDA pregnancy categories, are not applicable to this veterinary medicinal product.

Q: Does Carofertin carry a specific type of warning, such as a Boxed Warning in the US?

A: The product is regulated as a veterinary medicine and does not carry a U.S. Boxed Warning. Regulatory documents include special warnings primarily focused on the risk of accidental human self-injection and documented hypersensitivity reactions.

Q: What kind of monitoring or tests are typically recommended while a patient is taking Carofertin?

A: The official usage protocol emphasizes strict adherence to dose volume, injection route, and mandatory minimum time intervals between administrations. The regulatory documents do not detail routine testing or clinical monitoring recommendations.

Q: Do patients generally experience a withdrawal effect if they stop taking Carofertin suddenly?

A: No information on patient or animal withdrawal effects is provided in the official product information. The regulatory document only specifies the withdrawal period (the time before food products can enter the food chain), which is set at zero days/zero hours.

Q: What is the half-life of Carofertin, and why is this number important?

A: Studies on the active ingredient, Beta-Carotene, indicate it has an elimination half-life of approximately 5 to 7 days. The half-life value is used by pharmacologists to describe the rate at which the substance is eliminated from the body.

Q: Can Carofertin affect the results of routine lab tests or blood work?

A: Official information indicates that as a Beta-Carotene supplement, the medicine can potentially affect the results of blood tests used to measure Vitamin A or carotene levels.

How to Store and Dispose of Carofertin?

Storage Requirements

The storage of Carofertin (Beta-Carotene emulsion for injection) is strictly defined by official regulatory guidelines to ensure stability and safety. The product must not be stored above 25°C and it is essential that the medicine is not frozen. To protect the active ingredient from degradation, the container must be kept in the outer carton to shield it from light.

Stability and Child Safety

While the unopened product has a 3-year shelf-life, the contents must be used immediately after the immediate packaging is first opened. Any portion remaining after administration must be discarded immediately. Furthermore, the medicine must be stored out of the sight and reach of children at all times.

Disposal

Disposal of any unused Carofertin or related waste material is required to be carried out in accordance with local requirements for pharmaceutical waste.